Is PFE a buy? — what our data shows
Pfizer is one of the world's biggest pharmaceutical companies — it makes medicines, vaccines, and treatments for everything from cancer to infectious diseases, and most people know it from the COVID-19 vaccine it developed with BioNTech.
Everyone wishes they'd bought Nvidia early. Here's how to spot the next one.
The biggest winners of the last decade had one thing in common. Our data follows those exact moves — and turns them into 10 names to watch right now.
The big names in the AI, Space, Nuclear and Robotics race. The window to get in early is closing fast. Don't wait.
What our data shows
Our data on Pfizer is pretty limited, so let's be straight about that upfront. What we do have is 3 congressional trading disclosures — meaning three members of Congress reported making a trade in Pfizer stock. The names include Representatives Cisneros, Hill, and Letlow. Here's the thing though: these filings tell us a trade happened, but they don't tell us whether they were buying or selling — so we can't read too much into it either way.
The takeaway
With only a handful of congressional filings to go on, Pfizer is a name worth watching rather than drawing big conclusions from — if you're researching it seriously, this is one piece of a much larger puzzle.
Thinking about PFE?
Our data likes 10 other stocks even more right now — under-the-radar names we believe have monster upside potential. Get the free list before the crowd catches on.
Show me the 10 stocks — free →Have your own question?
Ask in plain English — our data answers. Free for retail readers.
Ask a question →Informational research, not personalized investment advice.